Literature DB >> 19710369

Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats.

Gregory T Collins1, Remy L Brim, Diwahar Narasimhan, Mei-Chuan Ko, Roger K Sunahara, Chang-Guo Zhan, James H Woods.   

Abstract

Cocaine esterase (CocE) is a naturally occurring bacterial enzyme, is a very efficient protein catalyst for the hydrolysis of cocaine, and has previously been shown to protect rodents from the lethal effects of cocaine. The current studies were aimed at evaluating the capacity of a longer acting mutant form (CocE T172R/G173Q; DM CocE) of CocE to protect against the lethal effects of cocaine, and alter ongoing intravenous cocaine self-administration in rats. A dose-response analysis revealed a dose-dependent suppression of cocaine-reinforced responding with 1.0 mg of CocE T172R/G173Q producing saline-like rates of responding. The effects of 1.0 mg of CocE T172R/G173Q on cocaine-reinforced responding were then compared with responding when saline was available for injection, whereas the selectivity of CocE T172R/G173Q's effects was assessed by evaluating the effects of 1.0 mg of CocE T172R/G173Q on (-)-2beta-carbomethoxy-3beta-phenyltropane (WIN-35065-2)- and food-reinforced responding. Although 1.0 mg of CocE T172R/G173Q suppressed responding maintained by 0.1 mg/kg/injection cocaine, a significant increase in responding was observed when responding was maintained by 1.0 mg/kg/injection cocaine, resulting in a 10-fold rightward shift in the dose-response curve for cocaine self-administration at a dose that did not significantly alter responding maintained by either WIN-35065-2 or food. These findings demonstrate that a long-acting form of CocE is effective at abruptly reducing the ongoing self-administration of low doses of cocaine, and provides a robust antagonism of cocaine's reinforcing effects. Furthermore, these studies provide strong evidence for the potential usefulness of a suitable, stable, and long-acting form of CocE as a pharmacotherapy for cocaine abuse in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710369      PMCID: PMC2775252          DOI: 10.1124/jpet.108.150029

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Authors:  John Grabowski; James Shearer; John Merrill; S Stevens Negus
Journal:  Addict Behav       Date:  2004-09       Impact factor: 3.913

Review 2.  Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.

Authors:  Amy Hauck Newman; Peter Grundt; Michael A Nader
Journal:  J Med Chem       Date:  2005-06-02       Impact factor: 7.446

Review 3.  Preclinical evaluation of the effects of buprenorphine, naltrexone and desipramine on cocaine self-administration.

Authors:  N K Mello
Journal:  NIDA Res Monogr       Date:  1990

Review 4.  Anti-cocaine catalytic antibodies--a novel approach to the problem of addiction.

Authors:  D W Landry; G X Yang
Journal:  J Addict Dis       Date:  1997

5.  Computational redesign of human butyrylcholinesterase for anticocaine medication.

Authors:  Yongmei Pan; Daquan Gao; Wenchao Yang; Hoon Cho; Guangfu Yang; Hsin-Hsiung Tai; Chang-Guo Zhan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

6.  Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase.

Authors:  Ziva D Cooper; Diwahar Narasimhan; Roger K Sunahara; Pawel Mierzejewski; Emily M Jutkiewicz; Nicholas A Larsen; Ian A Wilson; Donald W Landry; James H Woods
Journal:  Mol Pharmacol       Date:  2006-09-12       Impact factor: 4.436

7.  Vaccine pharmacotherapy for the treatment of cocaine dependence.

Authors:  Bridget A Martell; Ellen Mitchell; James Poling; Kishor Gonsai; Thomas R Kosten
Journal:  Biol Psychiatry       Date:  2005-07-15       Impact factor: 13.382

Review 8.  Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.

Authors:  F Ivy Carroll; James L Howard; Leonard L Howell; Barbara S Fox; Michael J Kuhar
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

9.  A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats.

Authors:  B Mets; G Winger; C Cabrera; S Seo; S Jamdar; G Yang; K Zhao; R J Briscoe; R Almonte; J H Woods; D W Landry
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Efficacy of a therapeutic cocaine vaccine in rodent models.

Authors:  B S Fox; K M Kantak; M A Edwards; K M Black; B K Bollinger; A J Botka; T L French; T L Thompson; V C Schad; J L Greenstein; M L Gefter; M A Exley; P A Swain; T J Briner
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

View more
  33 in total

1.  Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination.

Authors:  Tien-Yi Lee; Yoon Shin Park; George A Garcia; Roger K Sunahara; James H Woods; Victor C Yang
Journal:  Mol Pharm       Date:  2012-03-28       Impact factor: 4.939

2.  Repeated administration of a mutant cocaine esterase: effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys.

Authors:  Gregory T Collins; Remy L Brim; Kathleen R Noon; Diwahar Narasimhan; Nicholas W Lukacs; Roger K Sunahara; James H Woods; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2012-04-19       Impact factor: 4.030

Review 3.  Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction.

Authors:  Diwahar Narasimhan; James H Woods; Roger K Sunahara
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 4.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 5.  Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity.

Authors:  Charles W Schindler; Steven R Goldberg
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 6.  Cocaine hydrolase gene therapy for cocaine abuse.

Authors:  Stephen Brimijoin; Yang Gao
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

7.  Enzyme-therapy approaches for the treatment of drug overdose and addiction.

Authors:  Fang Zheng; Chang-Guo Zhan
Journal:  Future Med Chem       Date:  2011-01       Impact factor: 3.808

8.  Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase.

Authors:  Gregory T Collins; Kathy A Carey; Diwahar Narasimhan; Joseph Nichols; Aaron A Berlin; Nicholas W Lukacs; Roger K Sunahara; James H Woods; Mei-Chuan Ko
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

9.  Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats.

Authors:  Marilyn E Carroll; Yang Gao; Stephen Brimijoin; Justin J Anker
Journal:  Psychopharmacology (Berl)       Date:  2010-10-23       Impact factor: 4.530

10.  A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse.

Authors:  Remy L Brim; Mark R Nance; Daniel W Youngstrom; Diwahar Narasimhan; Chang-Guo Zhan; John J G Tesmer; Roger K Sunahara; James H Woods
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.